PMID- 24399714
OWN - NLM
STAT- MEDLINE
DCOM- 20140825
LR  - 20220408
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 65
IP  - 5
DP  - 2013
TI  - BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia 
      in Polish sample.
PG  - 1185-93
AB  - BACKGROUND: Deficit schizophrenia (DS) is distinguished from the group of 
      schizophrenic psychoses based on the presence of primary negative symptoms. It 
      differs from nondeficit (NDS) forms of schizophrenia in dimensions such as risk 
      factors, family history, course of illness and neurobiological differences. The 
      aim of the study was assessment of a potential association of the investigated 
      polymorphisms of the brain-derived neurotrophic factor (BDNF) and 
      catechol-O-methyltransferase (COMT) genes with the deficit syndrome in 
      schizophrenia. METHODS: A cohort of 200 patients with schizophrenia (81 DS and 
      119 NDS subjects) and a group of 100 control subjects matched for ethnicity, sex 
      and age were recruited. Somatic and psychometric assessment were conducted as 
      well as structured interview about the influence of adverse biological, family 
      and social factors. Genetic analysis of the BDNF (Val66Met) rs6265 and the COMT 
      (Val158Met) rs4680 polymorphisms was performed. RESULTS: We found significant 
      differences between DS and NDS in rs4680 COMT genotype distribution: more 
      homozygous Val/Val were found (31 vs. 17%) in the NDS compared to the DS 
      subgroup. No associations were found between the investigated polymorphisms of 
      the BDNF gene and the presence of schizophrenia either in DS and NDS subgroups. 
      CONCLUSION: The analysis of the COMT rs4680 polymorphism in the present DS and 
      NDS study shows that some genetic factors may be relevant in analyzing the 
      reasons for the differentiation of schizophrenic subtypes.
FAU - Pelka-Wysiecka, Justyna
AU  - Pelka-Wysiecka J
AD  - Department of Psychiatry, Pomeranian Medical University, Broniewskiego 26, PL 
      71-460 Szczecin, Poland. samoj@pum.edu.pl.
FAU - Wronski, Michal
AU  - Wronski M
FAU - Jasiewicz, Andrzej
AU  - Jasiewicz A
FAU - Grzywacz, Anna
AU  - Grzywacz A
FAU - Tybura, Piotr
AU  - Tybura P
FAU - Kucharska-Mazur, Jolanta
AU  - Kucharska-Mazur J
FAU - Bienkowski, Przemyslaw
AU  - Bienkowski P
FAU - Samochowiec, Jerzy
AU  - Samochowiec J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - EC 2.1.1.6 (COMT protein, human)
RN  - EC 2.1.1.6 (Catechol O-Methyltransferase)
SB  - IM
MH  - Adult
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Case-Control Studies
MH  - Catechol O-Methyltransferase/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Heterozygote
MH  - Homozygote
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Poland
MH  - *Polymorphism, Genetic
MH  - Risk Factors
MH  - Schizophrenia/classification/diagnosis/enzymology/*genetics
MH  - Schizophrenic Psychology
EDAT- 2014/01/09 06:00
MHDA- 2014/08/26 06:00
CRDT- 2014/01/09 06:00
PHST- 2013/01/07 00:00 [received]
PHST- 2013/04/10 00:00 [revised]
PHST- 2014/01/09 06:00 [entrez]
PHST- 2014/01/09 06:00 [pubmed]
PHST- 2014/08/26 06:00 [medline]
AID - S1734-1140(13)71476-2 [pii]
AID - 10.1016/s1734-1140(13)71476-2 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2013;65(5):1185-93. doi: 10.1016/s1734-1140(13)71476-2.